By Josh White
Date: Thursday 14 Aug 2025
(Sharecast News) - SkinBioTherapeutics said in an update on Thursday that revenue for the year ended 30 June were expected to rise almost fourfold to between £4.5m and £4.8m, driven by a full-year contribution from Dermatonics, eight months from Bio-Tech Solutions (BTS), and continued organic growth in AxisBiotix sales.
Proposed Placing of New Ordinary Shares | 14-Aug-2025 | 17:02 | RNS |
FY Trading Update | 14-Aug-2025 | 07:00 | RNS |
Transaction in Own Shares | 14-Aug-2025 | 07:00 | RNS |
Transaction in Own Shares | 14-Aug-2025 | 07:00 | RNS |
Launch of SlimBiome in leading US brand | 14-Aug-2025 | 07:00 | RNS |
Questor :GW Pharmaceuticals | 04-Dec-2014 | Telegraph |
Questor : Hikma Pharmaceuticals | 13-Mar-2014 | Telegraph |
Investment Column:BTG | 06-Oct-2011 | The Independent |
Investment Column:Genus | 09-Sep-2011 | The Independent |
Questor :Dechra Pharmaceuticals | 08-Sep-2011 | Telegraph |
Price | 21,587.38 |
Closing Price Change | 94.73 |
% Change | 0.44 % |
14-Aug-25 Close | 21,587.38 |
You are here: research